WeDaita · Platform Overview
BioMedAI —
From Research to Clinical
An integrated AI platform spanning the full drug discovery pipeline. One system. Three agent sets. Every stage from target identification to clinical execution.
The Drug Discovery Problem
90%
Attrition rate — 9 in 10 candidates fail before reaching patients
10–15 yrs
Average time from discovery to regulatory approval
$2–3B
Average cost per approved drug, largely driven by late-stage failures
The BioMedAI Pipeline
Three Agent Sets. One Integrated Platform.
Each agent set tackles a distinct phase of drug discovery — and passes outputs forward to the next stage.
Live Now
DBRA
Deep Biomedical Research Agents
Stage 1 — Early Research
90%
Reduction in early research time
- Target identification across 11+ databases
- Hypothesis generation with evidence tracing
- Biomarker discovery & pathway analysis
- Audit-ready research reports
In Development
ADDA
Autonomous Drug Design Agents
Stage 2 — Drug Design
70%
Faster drug design cycles (projected)
- Generative molecule & biologics design
- ADMET prediction & optimization
- Virtual screening & SAR analysis
- Synthesis feasibility scoring
Coming Soon
CTIA
Clinical Trial Intelligence Agents
Stage 3 — Clinical Trials
2×
Faster clinical trial execution (vision)
- AI-optimized trial protocol design
- Site intelligence & patient stratification
- Real-world evidence synthesis
- Regulatory submission support
DBRA outputs feed into ADDA
ADDA candidates feed into CTIA
Why BioMedAI
Built Different — End-to-End by Design
Integrated Pipeline, Not Point Solutions
Most AI drug discovery tools solve one step in isolation. BioMedAI is designed so each agent set feeds the next — your research intelligence compounds across stages.
Explainable & Audit-Ready
Every hypothesis, candidate, and output is traceable to its source evidence. BioMedAI doesn't just give answers — it shows its work, suitable for regulatory review.
Human-in-the-Loop by Design
AI generates, scientists decide. BioMedAI's agent workflow has built-in review checkpoints so your team stays in control of every key decision.
11+ Databases, Unified
PubMed, UniProt, ChEMBL, ClinicalTrials.gov, OpenTargets and more — queried simultaneously and synthesized into structured intelligence, not raw search results.
Speed That Compounds
DBRA alone cuts early research time by 90%. As ADDA and CTIA come online, that speed advantage extends across the full discovery timeline.
Biopharma-Grade Security
Built with enterprise security requirements in mind — data isolation, access controls, and audit logging for regulated environments.
Start with DBRA — Live Today
Cut 90% of your early research time. See how DBRA agents work on a real target.